← Back to Services💊Insilico Medicine — AI-Powered Drug Discovery Platform
ai-drug-discovery • Pharmaceutical & Biotech
Insilico Medicine uses generative AI and deep learning to discover new drug candidates in months instead of years. Their Pharma.AI platform generates novel molecular structures, predicts clinical trial outcomes, and identifies new disease targets. In 2023, Insilico advanced the first fully AI-discovered drug (for idiopathic pulmonary fibrosis) to Phase II clinical trials — a milestone that previously took the industry 4-5 years and $400M.
Features
- •Generative AI designs novel drug molecules from scratch in 30 days
- •Pharma.AI platform: target discovery → molecule generation → trial prediction
- •First AI-discovered drug in Phase II clinical trials (IPF treatment)
- •41 therapeutic programs in pipeline across cancer, fibrosis, and infectious disease
- •Biomarker AI predicts patient response before clinical trials begin
- •Partnerships with Sanofi, Menarini, and multiple top-20 pharma companies
Benefits
- •Reduce drug discovery timeline from 4.5 years to 18 months
- •Cut discovery costs from $400M to $50M per candidate
- •Higher clinical trial success rates via AI-predicted patient response
- •Address previously "undruggable" targets with novel molecular approaches
- •Accelerate treatments for rare diseases that lack commercial incentive